Is Selective Internal Radioembolization Safe and Effective for Patients with Inoperable Hepatocellular Carcinoma and Venous Thrombosis?

Journal of the American College of Surgeons

Volumn 208, Issue 3, 2009, Pages 375-382

  Woodall, Charles E ^a   Scoggins, Charles R ^a   Ellis, Susan F ^a   Tatum, Clifton M ^b   Hahl, Michael J ^b   Ravindra, Kadiyala V ^a   McMasters, Kelly M ^a   Martin II, Robert C G ^a  

^a University of Louisville School of Medicine   (United States)

^b Norton Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SELECTIVE INTERNAL RADIOEMBOLIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VENOUS THROMBOSIS; YTTRIUM RADIOISOTOPES;

EID: 60149084839     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.12.009     Document Type: Article

References (45)

1. Jepsen P., Vilstrup H., Tarone R.E., et al. Incidence rates of hepatocellular carcinoma in the US and Denmark: recent trends. Int J Cancer 121 (2007) 1624-1626
2. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 4 (1985) 918-928
3. Stuart K.E., Anand A.J., and Jenkins R.L. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer 77 (1996) 2217-2222
4. Di Bisceglie A.M., Rustgi V.K., Hoffnagle J.H., et al. Hepatocellular carcinoma. Ann Int Med 108 (1988) 390-401
5. Kassianides C., and Kew M.C. The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol Clin North Am 16 (1987) 553-562
6. th ed. (2002), Springer, New York
7. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
8. Minagawa M., and Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 12 (2006) 7561-7567
9. Garrean S., Hering J., Helton W.S., and Espat N.J. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. Am J Surg 194 (2007) 79-88
10. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 47 (2008) 82-89
11. Solomon B., Soulen M.C., Baum R.A., et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-c, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. JVIR 10 (1999) 793-798
12. Ramming K.P. The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors. Semin Oncol 10 (1983) 199-205
13. Nerenstone S., and Friedman J. Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 16 (1987) 603-612
14. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
15. Schenk Jr. W.G., McDonald J.C., McDonald K., and Drapanas T. Direct measurement of hepatic blood flow in surgical patients. Ann Surg 156 (1962) 463
16. Breedis C., and Young G. The blood supply of neoplasms in the liver. Am J Pathol (1954) 969-985
17. Madden M.V., Krige J.E.J., Bailey S., et al. Randomized trial of targeted chemotherapy with lipiodol and 5-epdoxorubicin compared with symptomatic treatment for hepatoma. Gut 34 (1993) 1598-1600
18. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332 (1995) 1256-1261
19. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11 (1990) 181-184
20. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27 (1998) 1578-1583
21. Uchida M., Khono H., Kubota H., et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 20 (1996) 326-331
22. Stuart K. Invited commentary on preoperative lipiodol for unresectable HCC. World J Surg 20 (1996) 331
23. Ehrhardt G.J., and Day D.E. Therapeutic use of Y-90 microspheres. Int J Radiat Appl Instrum Part B Nucl Med Biol 14 (1987) 233-242
24. Carr B.I. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10 Suppl 1 (2004) S107-S110
25. Steel J., Baum A., and Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology 13 (2004) 73-79
26. Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis 5 (2001) 109-122
27. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of non-resectable hepatocellular carcinoma with intrahepatic yttrium-90 microspheres. J Nucl Med 41 (2000) 1673-1681
28. Therasphere Package Insert. Ottawa, ON: MDS Nordion, Inc.
29. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http://ctep.cancer.gov Accessed August 9, 2006.
30. Ishikawa T., Imai M., Kamimura H., et al. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 13 (2007) 5465-5470
31. Sugiyama S., Beppu T., Ishiko T., et al. Efficacy of radiotherapy for PV and IVC tumor thrombosis in unresectable HCC. Hepatogastroenterology 54 (2007) 1779-1782
32. Kulik L.M., Carr B.I., Mulcahy M.F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47 (2008) 71-81
33. Salem R., Lewandowski R., Roberts C., et al. Use of yttrium-90 glass microspheres (Therasphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 15 (2004) 335-345
34. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 292 (2000) 205-216
35. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
36. Keppke A.L., Salem R., Reddy D., et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 188 (2007) 768-775
37. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007) 1753-1759
38. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (Therasphere): safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639
39. Kulik L.M., Atassi B., van Holsbeeck L., et al. Yttrium-90 microspheres (Therasphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94 (2006) 572-586
40. Kulik L.M., Mulcahy M.F., Hunter R.D., et al. Use of yttrium-90 microspheres (Therasphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 11 (2005) 1127-1131
41. Connolly G.C., Chen R., Hyrien O., et al. Incidence, risk factors, and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 122 (2008) 299-306
42. Lawrence T.S., Ten Haken R.K., Kessler M.L., et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 23 (1992) 781-788
43. Kim T.H., Kim D.Y., Park J.W., et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 29 (2006) 568-575
44. Kamiyama T., Nakanishi K., Yokoo H., et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Int J Clin Oncol 12 (2007) 363-368
45. Nakazawa T., Adachi S., Kitano M., et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology 73 (2008) 90-97